CommercialCoverageMedium impact
08.00.85q, Tocilizumab and Related Biosimilars for Intravenous Infusion
Independence Blue Cross·Rheumatology, Oncology, Internal Medicine·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
IBX updated their policy for tocilizumab and related biosimilar infusions, affecting coverage criteria, medical necessity requirements, and billing codes. This impacts reimbursement for intravenous tocilizumab treatments used primarily for rheumatoid arthritis and other autoimmune conditions.
Action Required
By July 1, 2025: Review updated IBX policy 08.00.85q for tocilizumab infusion coverage changes. Billing team must verify current medical necessity criteria and documentation requirements for tocilizumab and biosimilar claims. Update prior authorization processes if required. Review coding guidance for any changes to infusion billing.